Although there is no cure for ADPKD, tolvaptan, a selective vasopressin V2 receptor blocker, has been Food and Drug Administration approved as the first treatment to slow kidney function decline in adults at risk of rapidly progressing ADPKD.7 This evidence concerns the gene AVPR2 and autosomal dominant polycystic kidney disease.